Treatment intensification with abacavir in HIV-infected patients with at least 12 weeks previous lamivudine/zidovudine treatment

Antiviral Therapy

Volumn 6, Issue 2, 2001, Pages 135-142

  Rozenbaum, W ^a   Katlama, C ^a   Massip, P ^a   Bentata, M ^a   Zucman, D ^a   Delfraissy, J F ^a   Trepo, C ^a   David, F ^a   Lanier, E R ^a   Vavro, C ^a   Mamet, J P ^a  

^a HÔPITAL ROTHSCHILD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; LAMIVUDINE PLUS ZIDOVUDINE;

ARTICLE; ASTHENIA; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; PRIORITY JOURNAL; VIRUS MUTATION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-HIV AGENTS; DIDEOXYNUCLEOSIDES; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; RNA, VIRAL; TIME FACTORS; ZIDOVUDINE;

EID: 0034946783     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Treatment with lamivudine, zidovudine or both in HIV-positive patients with 200 to 500 CD4 cells per cubic millimetre
2. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral naive patients. A randomised controlled comparison with zidovudine monotherapy
3. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: The CAESAR trial
4. An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine
5. Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults
6. Ziagen (Abacavir, ABC, 1592) combined with 3TC and ZDV is highly effective and durable through 48 weeks in HIV-1 infected antiretroviral-therapy-naive subjects (CNA3003)
7. 96 Week experience with a class sparing triple reverse transcriptase nucleoside therapy regimen containing abacavir (1592, ABC)
8. Ziagen/Combivir is equivalent to indinavir/Combivir in antiretroviral therapy (ART) naive adults at 24 weeks (CNA3005)
9. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89
10. Rapid and simple method for purification of nucleic acids
11. The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1 infected individuals, including those without prior or concurrent zidovudine therapy
12. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs
13. The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: Results from a randomized, double-blind, trial
14. Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection
15. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
16. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
17. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity